» Authors » Florentia Kaguelidou

Florentia Kaguelidou

Explore the profile of Florentia Kaguelidou including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 73
Citations 678
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Landi A, Reggiardo G, Didio A, DErcole A, Ceci A, Govere G, et al.
Pediatr Rep . 2025 Feb; 17(1). PMID: 39997631
Background/objectives: This work aimed to analyze pediatric Post-Authorization Studies (PASs) registered in the European Union electronic Register of Post-Authorization Studies (EU PAS Register) from September 2010 to April 2023 to...
2.
Valtuille Z, Acquaviva E, Trebossen V, Ouldali N, Bourmaud A, Sclison S, et al.
J Pediatr . 2025 Feb; 280:114502. PMID: 39921118
Objective: To assess rates and trends of hypnotic medication prescriptions for children and adolescents. Study Design: Cross-sectional study of national dispensing data between January 1, 2016, and December 31, 2023,...
3.
Fafi I, Assad Z, Lenglart L, Valtuille Z, Kaguelidou F, Aupiais C, et al.
BMC Med . 2025 Feb; 23(1):66. PMID: 39901235
Background: Following non-pharmaceutical interventions (NPI) lifting in 2021, an important surge in childhood lower respiratory tract infections (LRTI) was reported in several countries, raising major concerns about the middle-term consequences...
4.
Assad Z, Trad M, Valtuille Z, Dumaine C, Faye A, Ikowsky T, et al.
Lancet Reg Health Eur . 2024 Dec; 49:101159. PMID: 39720096
Background: Scurvy, historically rare in-high income countries, has re-emerged as an indicator of socioeconomic and dietary disparities. Limited data exist on scurvy trends among European children, particularly following socioeconomic changes...
5.
Soeiro T, Allouchery M, Bene J, Bezin J, Dolladille C, Faillie J, et al.
Therapie . 2024 Dec; PMID: 39706774
The drug authorization process is shifting towards a policy aimed at shortening time-to-market. While this policy facilitates early access to new treatments, it can also result in potentially insufficient knowledge...
6.
Tisseyre M, Collier M, Beeker N, Kaguelidou F, Treluyer J, Chouchana L
Drug Saf . 2024 Dec; 48(3):265-277. PMID: 39630354
Introduction And Objective: Proton pump inhibitor (PPI) use in children increases the risk of infections, prompting inquiry into the impact of prenatal PPIs exposure on serious infections in offspring. As...
7.
Valtuille Z, Trebossen V, Ouldali N, Bourmaud A, Gandre C, Aupiais C, et al.
JAMA Netw Open . 2024 Oct; 7(10):e2441874. PMID: 39470637
Importance: Mental disorders among the pediatric population are a major area of public health concern. Little is known regarding changes in pediatric hospital resource use related to mental health (MH)...
8.
Ayme-Dietrich E, Kaguelidou F, Bertschy G, Chouchana L
Pharmacoepidemiol Drug Saf . 2024 Jun; 33(6):e5814. PMID: 38837561
Introduction: Methylphenidate (MPH) is a common treatment of attention-deficit/hyperactivity disorder (ADHD). Concern has been raised regarding its cardiovascular safety, partly in relation with its micromolar affinity for the 5-HT receptor,...
9.
Maillard O, Bun R, Laanani M, Verga-Gerard A, Leroy T, Gault N, et al.
Therapie . 2024 Jun; 79(6):659-669. PMID: 38834394
Aim Of The Study: The French National Health Data System (SNDS) comprises healthcare data that cover 99% of the population (over 67 million individuals) in France. The aim of this...
10.
Valtuille Z, Acquaviva E, Trebossen V, Ouldali N, Bourmaud A, Sclison S, et al.
JAMA Netw Open . 2024 Apr; 7(4):e247965. PMID: 38652474
Importance: Numerous studies have provided evidence for the negative associations of the COVID-19 pandemic with mental health, but data on the use of psychotropic medication in children and adolescents after...